Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 5/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15271397 | 0.83 | L3MBTL1 (0.45) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL7997948 | 0.79 | PLAU (0.45) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL339812 | 0.79 | MAPT (0.71) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL7400821 | 0.77 | MAOB (0.54) | MAPTHTR1ADRD2GAAABCB1 | |
| SCHEMBL4590099 | 0.76 | ALDH1A1 (0.50) | MAPTTDP1L3MBTL1GAA | |
| SCHEMBL1081189 | 0.74 | MAPT (0.59) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL29414783 | 0.74 | MAPT (0.59) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL21953183 | 0.74 | TDP1 (0.64) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL5538708 | 0.73 | MAPT (0.63) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL26013299 | 0.73 | MAPT (0.63) | MAPTMAPK1TDP1L3MBTL1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2022-10-06 | — | — | US | claimed |
| US-20210221789-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2021-07-22 | — | — | US | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| EP-0227011-B1 | Imidazole derivatives | SS PHARMACEUTICAL CO (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0352781-A2 | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-01-31 | — | — | EP | disclosed |
| US-4740601-A | Imidazole derivatives having antimicrobial activities | SS PHARMACEUTICAL CO., LTD. (JP) | 1988-04-26 | — | — | US | disclosed |
| EP-0227011-A2 | Imidazole derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 1987-07-01 | — | — | EP | disclosed |
| EP-0116787-B1 | 1,1-DIPHENYLPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Richter Gedeon Vegyészeti Gyár R.T. (HU) | 1987-03-18 | — | — | EP | disclosed |
| US-4605785-A | I(DUCE POLYSUBSTRATE MONOOXYGENASE ENZYME SYSTEM OF LIV)R WI HOUT GENTS | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1986-08-12 | — | — | US | disclosed |
| EP-0116787-A1 | 1,1-Diphenylpropanol derivatives, process for their preparation and pharmaceutical compositions containing them | Richter Gedeon Vegyészeti Gyár R.T. (HU) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221789-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 3890/4885MAPK1 2543/4885TDP1 2518/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | MAPT 3890/4885MAPK1 2543/4885TDP1 2518/4885 |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 3890/4885MAPK1 2543/4885TDP1 2518/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 3890/4885MAPK1 2543/4885TDP1 2518/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | MAPT 3062/4885MAPK1 3342/4885TDP1 1952/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 3890/4885MAPK1 2543/4885TDP1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.